Q32 Bio Inc (QTTB NASDAQ) stock market data APIs
$1.9355
0.03(1.5%)
as of September 12, 2025
Try our APIs with
free plan!
Q32 Bio Inc Financial Data Overview
Price chart is built with
Anychart
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Prev. Close
1.9355
Open
1.9625
High
2.0018
Low
1.8127
52 wk Range
1.345-53.17
Market Cap
23 541 K
Shares Outstanding
12 198 K
Revenue
-14 662 000
EPS
-0.78
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Q32 Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Q32 Bio Inc data using free add-ons & libraries
Get Q32 Bio Inc Fundamental Data
Q32 Bio Inc Fundamental data includes:
- Net Revenue: -14 662 000
- EBITDA: -54 287 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Q32 Bio Inc News
New
Q32 Bio August 2025 slides: Bempikibart shows durable response in alopecia areata
Introduction & Market Context Q32 Bio Inc (NASDAQ:QTTB) presented its corporate overview in August 2025, highlighting the company’s focus on immune therapeutics with a primary emphasis on its lead ...
Q32 Bio names interim chief medical officer
* Clinical-stage biotechnology company Q32 Bio (NASDAQ:QTTB [https://seekingalpha.com/symbol/QTTB]) appointed [https://seekingalpha.com/pr/20147073-q32-bio-appoints-adrien-sipos-m-d-ph-d-as-inte...
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results on 9 Apri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
